NextCell Pharma AB (OSTO:NXTCL) Total Assets : kr70.54 Mil (As of Feb. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Total Assets?

NextCell Pharma AB's Total Assets for the quarter that ended in Feb. 2024 was kr70.54 Mil.

Warning Sign:

If a company builds assets at 53.1% a year, faster than its revenue growth rate of 31.3% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, NextCell Pharma AB's average Total Assets Growth Rate was 38.50% per year. During the past 3 years, the average Total Assets Growth Rate was 70.60% per year. During the past 5 years, the average Total Assets Growth Rate was 53.10% per year.

During the past 9 years, NextCell Pharma AB's highest 3-Year average Total Assets Growth Rate was 70.60%. The lowest was 13.90%. And the median was 33.55%.

Total Assets is connected with ROA %. NextCell Pharma AB's annualized ROA % for the quarter that ended in Feb. 2024 was -53.21%. Total Assets is also linked to Revenue through Asset Turnover. NextCell Pharma AB's Asset Turnover for the quarter that ended in Feb. 2024 was 0.03.

NextCell Pharma AB Total Assets Historical Data

The historical data trend for NextCell Pharma AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Total Assets Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Total Assets

Get a 7-Day Free Trial

26.72

29.77

155.63

124.66

88.83

NextCell Pharma AB Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Assets	Get a 7-Day Free Trial															106.60	95.63	88.83	81.22	70.54

NextCell Pharma AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

NextCell Pharma AB's Total Assets for the fiscal year that ended in Aug. 2023 is calculated as

Total Assets	=	Total Equity (A: Aug. 2023 )	+	Total Liabilities (A: Aug. 2023 )
	=	75.727	+	13.1
	=	88.83

NextCell Pharma AB's Total Assets for the quarter that ended in Feb. 2024 is calculated as

Total Assets	=	Total Equity (Q: Feb. 2024 )	+	Total Liabilities (Q: Feb. 2024 )
	=	55.838	+	14.704
	=	70.54

NextCell Pharma AB (OSTO:NXTCL) Total Assets Explanation

Total Assets is connected with ROA %.

NextCell Pharma AB's annualized ROA % for the quarter that ended in Feb. 2024 is

ROA %	=	Net Income (Q: Feb. 2024 )	/	( (Total Assets (Q: Nov. 2023 )	+	Total Assets (Q: Feb. 2024 ))	/ count )
	=	-40.372	/	( (81.218	+	70.542)	/ 2 )
	=	-40.372	/	75.88
	=	-53.21 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

NextCell Pharma AB's Asset Turnover for the quarter that ended in Feb. 2024 is

	Asset Turnover
=	Revenue (Q: Feb. 2024 )	/	( (Total Assets (Q: Nov. 2023 )	+	Total Assets (Q: Feb. 2024 ))	/ count )
=	2.334	/	( (81.218	+	70.542)	/ 2 )
=	2.334	/	75.88
=	0.03

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

NextCell Pharma AB Total Assets Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB (OSTO:NXTCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

65G:Germany

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB (OSTO:NXTCL) Headlines

No Headlines